Сравнение
AOD-9604 vs. Sermorelin
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Рост
Рост
Номер CAS
221231-10-3
86168-78-7
Молекулярная масса
1815.09 g/mol
3358 g/mol
Период полувыведения
0.4 h
0.2 h
Последовательность
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheYADAIFTNSYRKVLGQLSARKLLQDIMSRМеханизм действия
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
3
5
из них на людях
2
3
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
3
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between AOD-9604 and Sermorelin?
- AOD-9604 is classified as "Рост", while Sermorelin is classified as "Рост". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, AOD-9604 or Sermorelin?
- The highest available evidence level is "РКИ на людях" for AOD-9604 and "РКИ на людях" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of AOD-9604 and Sermorelin in Germany and the United States?
- Германия: AOD-9604 — Не одобрено, Sermorelin — Не одобрено. США: AOD-9604 — Не одобрено, Sermorelin — Только для исследований. These are factual summaries with source and review date on the individual pages.